Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Statistics in Medicine|August 7, 2019
Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrenceBaldur P Magnusson, Heinz Schmidli, Nicolas Rouyrre, et al.Statistics in Medicine|February 26, 2011
A proof of concept phase II non-inferiority criterionBeat Neuenschwander, Nicolas Rouyrre, Norbert Hollaender, et al.Journal of Clinical Pharmacology|October 2, 2009
Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tractSreeraj Macha, Chan-Loi Yong, Thomas R MacGregor, et al.Current Medical Research and Opinion|March 30, 2020
Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosisImtiaz A Samjoo, Evelyn Worthington, Anja Haltner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumorsKlaus Mross, Annette Frost, Simone Steinbild, et al.European Journal of Neurology|June 8, 2026
Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND StudyPatrick Vermersch, Sophie Arnould, Ralf Gold, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2020
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosisBruce Ac Cree, Baldur Magnusson, Nicolas Rouyrre, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2022
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 yearsBruce Ac Cree, Douglas L Arnold, Robert J Fox, et al.Journal of Neurology|May 31, 2022
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND studyRalf Gold, Daniela Piani-Meier, Ludwig Kappos, et al.Lancet (London, England)|December 26, 2015
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyJames C Yao, Nicola Fazio, Simron Singh, et al.Pageof 1